Intra-Cellular Therapies, Inc. Quarterly Net Income (Loss) Attributable to Parent in USD from Q1 2013 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Intra-Cellular Therapies, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from Q1 2013 to Q3 2024.
  • Intra-Cellular Therapies, Inc. Net Income (Loss) Attributable to Parent for the quarter ending September 30, 2024 was -$26.3M, a 8.52% decline year-over-year.
  • Intra-Cellular Therapies, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending September 30, 2024 was -$86.4M, a 44.3% increase year-over-year.
  • Intra-Cellular Therapies, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$140M, a 45.5% increase from 2022.
  • Intra-Cellular Therapies, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$256M, a 9.81% increase from 2021.
  • Intra-Cellular Therapies, Inc. annual Net Income (Loss) Attributable to Parent for 2021 was -$284M, a 25.2% decline from 2020.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 -$86.4M -$26.3M -$2.07M -8.52% Jul 1, 2024 Sep 30, 2024 10-Q 2024-10-30
Q2 2024 -$84.3M -$16.2M +$26.6M +62.1% Apr 1, 2024 Jun 30, 2024 10-Q 2024-10-30
Q1 2024 -$111M -$15.2M +$28.8M +65.4% Jan 1, 2024 Mar 31, 2024 10-Q 2024-10-30
Q4 2023 -$140M -$28.6M +$15.4M +35.1% Oct 1, 2023 Dec 31, 2023 10-K 2024-02-22
Q3 2023 -$155M -$24.3M +$29.3M +54.7% Jul 1, 2023 Sep 30, 2023 10-Q 2024-10-30
Q2 2023 -$184M -$42.8M +$43.8M +50.6% Apr 1, 2023 Jun 30, 2023 10-Q 2024-10-30
Q1 2023 -$228M -$44.1M +$28.1M +38.9% Jan 1, 2023 Mar 31, 2023 10-Q 2024-10-30
Q4 2022 -$256M -$44M +$41.7M +48.6% Oct 1, 2022 Dec 31, 2022 10-K 2024-02-22
Q3 2022 -$298M -$53.5M +$23.4M +30.4% Jul 1, 2022 Sep 30, 2022 10-K 2024-02-22
Q2 2022 -$321M -$86.6M -$17.9M -26% Apr 1, 2022 Jun 30, 2022 10-K 2024-02-22
Q1 2022 -$304M -$72.1M -$19.4M -36.7% Jan 1, 2022 Mar 31, 2022 10-K 2024-02-22
Q4 2021 -$284M -$85.7M -$25M -41.2% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-01
Q3 2021 -$259M -$76.9M -$21.7M -39.4% Jul 1, 2021 Sep 30, 2021 10-K 2023-03-01
Q2 2021 -$237M -$68.7M -$5.03M -7.9% Apr 1, 2021 Jun 30, 2021 10-K 2023-03-01
Q1 2021 -$232M -$52.7M -$5.33M -11.2% Jan 1, 2021 Mar 31, 2021 10-K 2023-03-01
Q4 2020 -$227M -$60.7M -$20.1M -49.6% Oct 1, 2020 Dec 31, 2020 10-K 2022-03-01
Q3 2020 -$207M -$55.2M -$20.3M -58.3% Jul 1, 2020 Sep 30, 2020 10-K 2022-03-01
Q2 2020 -$187M -$63.7M -$26.3M -70.2% Apr 1, 2020 Jun 30, 2020 10-K 2022-03-01
Q1 2020 -$160M -$47.4M -$12.6M -36.1% Jan 1, 2020 Mar 31, 2020 10-K 2022-03-01
Q4 2019 -$148M -$40.6M +$165K +0.41% Oct 1, 2019 Dec 31, 2019 10-K 2021-02-25
Q3 2019 -$148M -$34.9M +$6.66M +16% Jul 1, 2019 Sep 30, 2019 10-K 2021-02-25
Q2 2019 -$155M -$37.4M -$64.8K -0.17% Apr 1, 2019 Jun 30, 2019 10-K 2021-02-25
Q1 2019 -$154M -$34.8M +$644K +1.82% Jan 1, 2019 Mar 31, 2019 10-K 2021-02-25
Q4 2018 -$155M -$40.7M -$10.5M -34.9% Oct 1, 2018 Dec 31, 2018 10-K 2020-03-02
Q3 2018 -$145M -$41.5M -$18.7M -81.6% Jul 1, 2018 Sep 30, 2018 10-K 2020-03-02
Q2 2018 -$126M -$37.4M -$19.6M -110% Apr 1, 2018 Jun 30, 2018 10-K 2020-03-02
Q1 2018 -$106M -$35.5M -$8.55M -31.7% Jan 1, 2018 Mar 31, 2018 10-K 2020-03-02
Q4 2017 -$97.8M -$30.2M -$2.72M -9.91% Oct 1, 2017 Dec 31, 2017 10-K 2019-02-27
Q3 2017 -$95M -$22.9M +$7.39M +24.4% Jul 1, 2017 Sep 30, 2017 10-K 2019-02-27
Q2 2017 -$102M -$17.8M +$13.1M +42.4% Apr 1, 2017 Jun 30, 2017 10-K 2019-02-27
Q1 2017 -$116M -$26.9M +$908K +3.26% Jan 1, 2017 Mar 31, 2017 10-K 2019-02-27
Q4 2016 -$116M -$27.5M +$1.35M +4.68% Oct 1, 2016 Dec 31, 2016 10-K 2018-03-01
Q3 2016 -$118M -$30.3M +$1.9M +5.89% Jul 1, 2016 Sep 30, 2016 10-K 2018-03-01
Q2 2016 -$120M -$30.8M -$9.32M -43.3% Apr 1, 2016 Jun 30, 2016 10-K 2018-03-01
Q1 2016 -$110M -$27.8M -$5.55M -24.9% Jan 1, 2016 Mar 31, 2016 10-K 2018-03-01
Q4 2015 -$105M -$28.8M -$13.6M -89.7% Oct 1, 2015 Dec 31, 2015 10-K 2017-03-01
Q3 2015 -$91.2M -$32.2M -$25.7M -401% Jul 1, 2015 Sep 30, 2015 10-K 2017-03-01
Q2 2015 -$65.4M -$21.5M -$17M -374% Apr 1, 2015 Jun 30, 2015 10-K 2017-03-01
Q1 2015 -$48.4M -$22.3M -$17.7M -391% Jan 1, 2015 Mar 31, 2015 10-K 2017-03-01
Q4 2014 -$30.7M -$15.2M -$7.16M -89% Oct 1, 2014 Dec 31, 2014 10-K 2016-02-25
Q3 2014 -$23.5M -$6.42M -$1.5M -30.6% Jul 1, 2014 Sep 30, 2014 10-K 2016-02-25
Q2 2014 -$22M -$4.53M +$3.74M +45.2% Apr 1, 2014 Jun 30, 2014 10-K 2016-02-25
Q1 2014 -$25.8M -$4.54M +$1.1M +19.4% Jan 1, 2014 Mar 31, 2014 10-K 2016-02-25
Q4 2013 -$26.9M -$8.04M Oct 1, 2013 Dec 31, 2013 10-K 2015-03-12
Q3 2013 -$4.91M Jul 1, 2013 Sep 30, 2013 10-K 2015-03-12
Q2 2013 -$8.28M Apr 1, 2013 Jun 30, 2013 10-K 2015-03-12
Q1 2013 -$5.64M Jan 1, 2013 Mar 31, 2013 10-K 2015-03-12
* An asterisk sign (*) next to the value indicates that the value is likely invalid.